Illidge, T., Bouabdallah, R., Chen, R., Gopal, A.K., Moskowitz, C.H., Ramchandren, R., Shustov, A.R., Tilly, H., Trippett, T.M., Gibb, A., Grove, L.E. and Advani, R. (2015) Allogeneic Transplant Following Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma. Leuk Lymphoma, 56, 703-710.
https://doi.org/10.3109/10428194.2014.930852

has been cited by the following article:

• TITLE: Brentuximab Vedotin Monotherapy and Combined with Low Dose Donor Lymphocyte Infusion to Control Minimal Residual Disease and Sustain Clinical Remission in a Child with Relapsed Anaplastic Large Cell Lymphoma

  AUTHORS: Alina S. Fedorova, Maria V. Stegantseva, Nina V. Minakovskaya, Olga V. Aleinikova

  KEYWORDS: Anaplastic Large Cell Lymphoma, Relapse, Brentuximab Vedotin, Donor Lymphocyte Infusion, Minimal Residual Disease

  JOURNAL NAME: Journal of Cancer Therapy, Vol.8 No.8, July 28, 2017

  ABSTRACT: Minimal residual disease (MRD) appears to have a strong negative predictive value for disease recurrence in children with anaplastic large cell lymphoma (ALCL). Brentuximab vedotin (BV) can be a therapeutic option for MRD-positive patients to achieve molecular remission and to decrease risk of subsequent relapse. We here report a 4-year-old child with ALCL progression during relapse treatment who received BV as a bridging therapy before haploidentical hematopoietic stem-cell transplantation, and as a maintenance therapy post-transplant alone or combined with simultaneous low dose donor-lymphocyte infusions. MRD monitoring showed a complete molecular response and reflected both BV efficiency and graft-versus-lymphoma effect.